⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicotinyl Alcohol SCHEMBL2848961 | 1.00 | — | — | |
| Nicotinyl Alcohol SCHEMBL29410207 | 0.98 | — | — | |
| Nicotinyl Alcohol SCHEMBL16266 | 0.98 | — | — | |
| Nicotinyl Alcohol SCHEMBL4881447 | 0.98 | KDM4E (0.69) | — | |
| Nicotinyl Alcohol SCHEMBL8747733 | 0.95 | — | — | |
| Nicotinyl Alcohol SCHEMBL27584606 | 0.95 | KDM4E (0.67) | — | |
| Nicotinyl Alcohol SCHEMBL28350013 | 0.95 | KDM4E (0.67) | — | |
| Nicotinyl Alcohol SCHEMBL28177623 | 0.95 | — | — | |
| Nicotinyl Alcohol SCHEMBL2476584 | 0.93 | KDM4E (0.65) | — | |
| Nicotinyl Alcohol SCHEMBL16986785 | 0.93 | KDM4E (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284631-A1 | FLUORIDE CATALYZED POLYSILOXANE DEPOLYMERIZATION | Bowling Green State University (US) | 2023-12-06 | — | — | EP | claimed |
| WO-2022165305-A1 | FLUORIDE CATALYZED POLYSILOXANE DEPOLYMERIZATION | BOWLING GREEN STATE UNIVERSITY (US) | 2022-08-04 | — | — | WO | claimed |
| EP-3827015-B1 | GIP/GLP1 CO-AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320527-A1 | DNA EDITING USING SINGLE-STRANDED DNA | UNIV NEBRASKA (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4604986-A2 | LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF | Eli Lilly and Company (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250241995-A1 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | ELI LILLY AND COMPANY | 2025-07-31 | — | — | US | disclosed |
| US-12318463-B2 | Compositions and methods for treating canker sores | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2025109288-A1 | ORO-DENTAL COMPOSITION COMPRISING AN ABRASIVE FILLER | PIERRE FABRE MEDICAMENT (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025109287-A1 | ORO-DENTAL COMPOSITION | PIERRE FABRE MEDICAMENT (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4549454-A2 | GIP/GLP1 CO-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-112840011-B | Consumer product and delivery system using organoleptic compounds | 宝洁公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11345766-B2 | Tetrahydro-as-indacenyl catalyst composition, catalyst system, and processes for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3452520-B1 | TETRAHYDRO-AS-INDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220090521-A1 | USE OF PERFLUOROHEPTENES IN POWER CYCLE SYSTEMS | THE CHEMOURS COMPANY FC, LLC (US) | 2022-03-24 | — | — | US | disclosed |
| CN-108368502-B | DNA editing using single-stranded DNA | 内布拉斯加大学董事委员会 | 2022-03-18 | — | — | CN | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220048086-A1 | PRESS BRAKE AND MANAGEMENT SYSTEM | AMADA CO., LTD. (JP) | 2022-02-17 | — | — | US | disclosed |
| CN-114019171-A | Blood preparation and profiling | 善威生物私人有限公司 | 2022-02-08 | — | — | CN | disclosed |